{'fraction_non_alphanumeric': 0.02356020942408377, 'fraction_numerical': 0.010471204188481676, 'mean_word_length': 5.322314049586777, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Early androgen deprivation for prostate cancer?

The dependence of the growth of prostate cancer on androgens is well documented. Androgen ablation triggers a cascade of biologic events that ends in irreversible damage to the DNA of androgen-sensitive prostate-cancer cells.1 Such treatment, traditionally reserved for men with metastatic disease, results in major objective and subjective benefits in most patients. However, in approximately 50 percent of patients, disease progression occurs 12 to 18 months after the initiation of treatment, and as a result, survival rates have not increased over the past five decades.2 Androgen ablation controls the tumor only temporarily because prostate cancer consists of androgen-dependent and androgen-independent . . .